| NCT01851369 | II | Granulosa cell ovarian cancer | A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas | MD | View Drugs | View Results |
Methoxyamine | TRC102 | Base excision repair inhibitor | Clinical Trials | Temozolomide | Temodal, Temodar, Methazolastone | DNA damaging agent | Approved in Other Cancers |
|
|
| NCT03428802 | II | Advanced solid tumors with high MSI and with POLE, POLD, or BRCA1/2 mutations | A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability | NJ, NY | View Drugs | View Results |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03462342 | II | Platinum sensitive high grade serous ovarian cancer (cohort A), or platinum sensitive high grade serous ovarian cancer with BRCA1/2 mutations or HRD+ w/ clinical benefit of PARPi therapy followed by progression in most recent prior regimen (cohort DII) | Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian Cancer | MD, MA, PA | View Drugs | View Results |
Ceralasertib | ATR kinase inhibitor AZD6738, AZD6738 | ATR kinase inhibitor | Clinical Trials | Olaparib | Lynparza, AZD2281 | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03579316 | II | Platinum sensitive ovarian cancer with BRCA1/2 mutations or HRD+ that must have benefited from and then progressed on prior PARP inhibitor | EFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP Inhibition | MA, TX | View Drugs | View Results |
Ceralasertib | ATR kinase inhibitor AZD6738, AZD6738 | ATR kinase inhibitor | Clinical Trials | Olaparib | Lynparza, AZD2281 | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03682289 | II | Advanced solid tumors with ARID1A or ATM alterations | Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor Malignancies | CA | View Drugs | View Results |
Ceralasertib | ATR kinase inhibitor AZD6738, AZD6738 | ATR kinase inhibitor | Clinical Trials | Olaparib | Lynparza, AZD2281 | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03693014 | II | Advanced solid tumors with dMMR, high TMB or high MSI with limited progression on checkpoint inhibitor treatment | A Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint Blockade | CT, NJ, NY, PA | View Drugs | View Results |
Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Radiation Therapy | Irradiation, Radiotherapy | | |
|
|
| NCT03732950 | II | Recurrent ovarian cancer | A Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression Profiling | CA, MN | View Drugs | View Results |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03734692 | II | Platinum sensitive ovarian cancer with first or second recurrence in peritoneal cavity | Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer | PA | View Drugs | View Results |
Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Rintatolimod | Atvogen | TLR3 agonist and immune cell stimulator | Approved in Other Indications |
|
|
| NCT03878849 | II | Recurrent ovarian cancer | Phase II, Prospective Open Label, Single Arm Study to Investigate Anti-tumor Effect and Tolerability of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP® | OK, WA | View Drugs | View Results |
Stenoparib | PARP/Tankyrase inhibitor 2X-121, E7449, 2X-121 | PARP inhibitor | Clinical Trials |
|
|
| NCT03911557 | II | Advanced solid tumors with moderate/high TMB | Phase 2 Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors | KY | View Drugs | View Results |
Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Tremelimumab | Ticilimumab, CP-675206, CP-675,206, CP-675, anti-CTLA4 human monoclonal antibody CP-675,206 | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03907475 | II | Advanced solid tumors (with tumor amenable to skin biopsy) | DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors | MD | View Drugs | View Results |
Capecitabine | Xeloda, CAPE | RNA processing and thymidylate synthase inhibitor | NCCN Guidelines for Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | nab-Paclitaxel | Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007 | Microtubule stabilizer/mitotic inhibitor | NCCN Guidelines for Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT02710253 | II | Advanced solid tumors that must have progressed on prior immunotherapy or cellular therapy (amenable to radiation therapy) | Phase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic Immunotherapy | TX | View Drugs | View Results |
Radiation Therapy | Irradiation, Radiotherapy | | |
|
|
| NCT03449108 | II | Recurrent high grade ovarian cancer or carcinosarcoma | Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types | TX | View Drugs | View Results |
Aldesleukin | | IL-2R agonist | Approved in Other Cancers | Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | LN-145-S1 | Autologous Tumor Infiltrating Lymphocytes LN-145-S1, PD-1 selected TIL therapy | Immune response against tumor-associated antigens | Clinical Trials | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03994796 | II | Advanced solid tumors with brain metastases and NTRK, ROS1, CDK pathway or PI3K pathway alterations | Genomically-Guided Treatment Trial in Brain Metastases | AK, AZ, AR, CA, CO, CT, FL, GA, ID, IL, IA, KS, KY, LA, MA, MI, MN, MS, MO, MT, NE, NH, NJ, NY, NC, OH, OK, OR, PA, TX, UT, VT, VA, WA, WI, WY | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | Entrectinib | RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek | ALK, TRK, ROS1 kinase inhibitor | Approved in Other Cancers | Paxalisib | GDC-0084, PI3K inhibitor GDC-0084, RG7666 | PI3K/mTOR inhibitor | Clinical Trials |
|
|
| NCT04449549 | II | Recurrent rare tumors | Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel | MD | View Drugs | View Results |
Nilotinib | AMN 107, Tasigna | Bcr-abl, c-Kit, and PDGFR kinase inhibitor | Approved in Other Cancers | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04469764 | II | Recurrent ovarian cancer with CCND1-3 or CDK4/6 amplifications or CDKN2A alterations | An Open Label Phase II Study of the Efficacy and Safety of Abemaciclib, a Cyclin Dependent Kinase (CDK4/6) Inhibitor in Selected Patients With Recurrent Ovarian or Endometrial Cancer | CA | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | Anastrozole | Arimidex | Aromatase inhibitor | | Letrozole | Femara | Aromatase inhibitor | NCCN Guidelines for Ovarian Cancer |
|
|
| NCT04534283 | II | Advanced solid tumors with alterations in BRAF, RAF1, MEK1/2, ERK1/2 or NF1 | A Phase 2 Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib for Patients Whose Tumors Harbor Pathogenic Alterations in BRAF, RAF1, MEK1/2, ERK1/2, and NF1. | IN | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | Temuterkib | LY3214996 | ERK inhibitor | Clinical Trials |
|
|
| NCT04550494 | II | Advanced solid tumors with alterations in ARID1A, ATM, ATR, BAP1, BARD1, BRCA 1/2, BRIP1, CDK12, CHK1/2, FANCA/B/C/D2/E/F/G/I/J/L/M/N, IDH1/2, MRE11A, NBN, PALB2, RAD50/51/51B/51C/51D or RAD54L (only 1 prior platinum therapy; germ-line BRCA MUT patients must have progressed on prior PARP inhibitor) | A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response | FL, MD, OK | View Drugs | View Results |
Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers |
|
|
| NCT04592653 | II | Recurrent ovarian cancer | Clinical and Immunologic Activity of Nemvaleukin Alfa With Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3 | MI, TX, UT, VA | View Drugs | View Results |
Nemvaleukin alfa | intermediate-affinity interleukin-2 receptor agonist ALKS 4230, Nemvaleukin, ALKS4230 | IL-2R/IL-15R beta and gamma agonist | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04589845 | II | Advanced solid tumors with alterations in AKT1/2/3, ALK, ERBB2, MDM2, NTRK1/2/3, PIK3CA (multiple mutations), ROS1 or with high TMB | Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial | AL, AZ, CA, FL, GA, ID, MD, MI, MN, MT, NH, NJ, NM, NY, OH, OR, PA, TN, TX, VA, WA, WI | View Drugs | View Results |
Alectinib | AF802, anaplastic lymphoma kinase inhibitor CH5424802, Alecensa, ALK inhibitor CH5424802 | ALK kinase inhibitor | Approved in Other Cancers | Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Entrectinib | RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek | ALK, TRK, ROS1 kinase inhibitor | Approved in Other Cancers | Idasanutlin | MDM2 antagonist RO5503781, RG7388, RO5503781 | MDM2 antagonist | Clinical Trials | Inavolisib | RG6114, GDC-0077 | PI3K alpha inhibitor | Clinical Trials | Ipatasertib | GDC-0068, Akt Inhibitor GDC-0068, RG7440 | pan-AKT inhibitor | Clinical Trials | Trastuzumab emtansine | trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine | ADC: anti-HER2 + microtubule destabilizer (DM1) | Approved in Other Cancers |
|
|
| NCT04625270 | II | Recurrent low grade serous ovarian cancer | A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) | AZ, CA, CT, FL, IL, MD, MN, MO, NV, NM, NY, OH, OK, OR, TN, TX, VA | View Drugs | View Results |
Avutometinib | CH5126766, Raf/MEK dual kinase inhibitor RO5126766, RO5126766, CKI27, VS-6766 | RAF and MEK inhibitor | Clinical Trials | Defactinib | VS-6063, PF-04554878, PF-04554878 | FAK inhibitor | Clinical Trials |
|
|
| NCT04729348 | II | Advanced solid tumors with leptomeningeal metastases | Phase II Trial of Pembrolizumab and Lenvatinib for Leptomeningeal Metastases | MA | View Drugs | |
Lenvatinib | MK-7902, Lenvima, ER-203492-00, E7080 | Multi-targeted RTK inhibitor | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04739618 | II | Advanced solid tumors - intratumoral injection | A Phase 2 Trial of Non-ablative Cryosurgical Freezing and Multiplex Immunotherapy in Patients With Metastatic Solid Cancer | AZ | View Drugs | View Results |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Thermotherapy | | | Clinical Trials |
|
|
| NCT04771520 | II | Advanced solid tumors with c-Kit or PDGFRA mutations (except c-KIT V654A or T670I) | Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid Tumors | TX | View Drugs | |
Avapritinib | | PDGFRa and c-Kit inhibitor | Approved in Other Cancers |
|
|
| NCT02896335 | II | Patients with progressive brain metastases with amplifications in CDK4, CDK6, CCND1, CCND2, CCND3 or CCNE1 or loss of CDKN2A | A Phase 2 Study of Palbociclib in Progressive Brain Metastases Harboring Alterations in the CDK Pathway | MA | View Drugs | View Results |
Palbociclib | PD-0332991, PD0332991, Ibrance | CDK4/6 inhibitor | Approved in Other Cancers |
|
|
| NCT04919629 | II | Recurrent ovarian cancer with symptomatic ascites or pleural effusion | Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant Effusion | NY | View Drugs | |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Pegcetacoplan | C3-targeted complement inhibitor APL-2, APL-2 | Blocks the cleavage of C3 | Approved in Other Indications | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04957615 | II | Advanced solid tumors with ARID1A mutations | A Phase II Clinical Trial to Investigate ARID1A Mutation and CXCL13 Expression in the Pre-Treatment Tumor Samples as a Combinatorial Predictive Biomarker for Immune Checkpoint Therapy in Metastatic Solid Tumors | TX | View Drugs | |
Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05064280 | II | Advanced solid tumors with brain metastases | Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases | TX | View Drugs | View Results |
Lenvatinib | MK-7902, Lenvima, ER-203492-00, E7080 | Multi-targeted RTK inhibitor | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05071937 | II | Recurrent ovarian cancer with prior PARP inhibitor (at most 4 prior chemotherapy regimens) | Phase ll Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Talazoparib, in Patients With Recurrent Ovarian Cancer | PA | View Drugs | View Results |
Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers | ZEN-3694 | ZEN003694, BET bromodomain inhibitor ZEN-3694 | BET inhibitor | Clinical Trials |
|
|
| NCT05082025 | II | Recurrent ER+ and/or PR+ ovarian cancer with alterations in PIK3CA, PIK3R1 or PTEN | Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations | TX | View Drugs | View Results |
Copanlisib | BAY 80-6946, PI3K inhibitor BAY 80-6946 | pan-PI3K inhibitor | Approved in Other Cancers | Fulvestrant | ZD9238, ICI 182,780, Faslodex | ER antagonist (SERD) | Approved in Other Cancers |
|
|
| NCT05097599 | II | Advanced solid tumors with ALK or ROS1 fusions, BRAF V600X, BRCA1/2, or gPALB2 alterations, or HER2+, Nectin-4+ or TROP2+, or IRS-H+ or Angio TRS-H+ | Strata PATH™ (Precision Indications for Approved Therapies): A Study Evaluating the Clinical Activity and Safety of Approved Drugs Within Biomarker-Guided Patients With Solid Tumors | AR, DE, FL, IA, LA, OH, TN, WI | View Drugs | |
Axitinib | Inlyta, AG-013736 | Multi-targeted RTK inhibitor | | Binimetinib | MEK162, MEK inhibitor MEK162, ARRY-162, ARRY-438162, Mektovi | MEK inhibitor | Approved in Other Cancers | Encorafenib | Raf Kinase Inhibitor LGX818, LGX818 | RAF inhibitor | Approved in Other Cancers | Enfortumab Vedotin | | ADC: anti-Nectin-4 + microtubule destabilizer (MMAE) | Approved in Other Cancers | Lorlatinib | PF-06463922 | ALK and ROS1 kinase inhibitor | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Sacituzumab govitecan | Trodelvy, hrS7-SN38 antibody drug conjugate, anti-TROP-2 Antibody-Drug Conjugate IMMU-132 | ADC: anti-TROP2 + topoisomerase I inhibitor (SN38) | Approved in Other Cancers | Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers | Trastuzumab deruxtecan | T-Dxd, DS-8201, fam-trastuzumab deruxtecan-nxki, ADC DS-8201a, anti-HER2 antibody-drug conjugate DS-8201a, anti-HER2 ADC DS-8201a, DS-8201a | ADC: anti-HER2 + topoisomerase I inhibitor (Dxd) | Approved in Other Cancers |
|
|
| NCT05113368 | II | Recurrect low grade serous ovarian cancer | Efficacy of Oral Regorafenib Combined With Intra-muscular Injection of Fulvestrant in Patients With Recurrent Low-grade Serous Ovarian Cancer: A Phase II Single Arm Trial | PA | View Drugs | |
Fulvestrant | ZD9238, ICI 182,780, Faslodex | ER antagonist (SERD) | Approved in Other Cancers | Regorafanib | BAY73-4506, multikinase inhibitor BAY 73-4506, Stivarga | Multi-targeted RTK inhibitor | Approved in Other Cancers |
|
|
| NCT05185947 | II | Recurrent or persistent non-mucinous ovarian cancer with peritoneal disease (IP/IV) | Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Ovarian, or Other Gynecologic Primary Cancer | MD | View Drugs | View Results |
Nilotinib | AMN 107, Tasigna | Bcr-abl, c-Kit, and PDGFR kinase inhibitor | Approved in Other Cancers | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT05199584 | II | Advanced solid tumors with loss of function PTCH1 mutations | A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations | CA, FL, IL, LA, NV, NY, NC, OH, PA, TN, TX, VA, WI | View Drugs | |
Taladegib | LY2940680, ENV-101 | Smoothened antagonist | Clinical Trials |
|
|
| NCT04992013 | II | Ovarian cancer with brain metastases and alterations in ATM, ATR, BAP1, BARD1, BRCA1/2, BRIP1, MRE11A, NBN, PALB2, RAD50, RAD51B/C/D, RAD54B/L, XRCC2, or XRCC3 (with measurable disease in the CNS) | Genomically Guided Phase II Study to Evaluate the Clinical Benefit of Niraparib in Tumors Metastatic to the CNS | MA | View Drugs | View Results |
|
|
| NCT05231122 | II | Recurrent serous, endometrioid or clear cell ovarian cancer | Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer | NY, TX | View Drugs | View Results |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | CDX-1140 | | Stimulates CD40 to increase/activate antigen-presenting cells and enhance immune response | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05286801 | II | Advanced solid tumors with loss of SMARCB1 or SMARCA1 | A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | AL, CA, CO, DC, IL, IN, MD, MA, MI, MN, MO, NY, NC, OH, PA, TN, TX | View Drugs | View Results |
Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Tiragolumab | MTIG7192A, RO7092284 | Blocks TIGIT binding to PVR (CD155) and PVRL2 (CD112) to enable DNAM-1 (CD226) mediated activation of NK and CD8 T cells | Clinical Trials |
|
|
| NCT05296512 | II | Recurrent or persistent clear cell ovarian cancer | A Phase II Trial of Pembrolizumab and Lenvatinib in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary | MA | View Drugs | View Results |
Lenvatinib | MK-7902, Lenvima, ER-203492-00, E7080 | Multi-targeted RTK inhibitor | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05318573 | II | Advanced solid tumors | A Phase 2a Study With Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | NJ, NY, OR, PA | View Drugs | View Results |
FF-10832 Gemcitabine Liposome | | Ribonucleotide reductase and DNA synthesis inhibitor | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05327010 | II | Advanced solid tumors with alterations in BARD1, BRCA 1/2, BRIP1, FANCA, PALB2; RAD51 or RAD51C/D with PARP inhibitor therapy as immediate prior therapy or advanced solid tumors with a KRAS G12C mutation with prior KRAS G12C targeted therapy or platinum sensitive ovarian cancer without BRCA1/2 mutations with CR/PR on prior PARP inhibitor | Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET) | CO, GA, IL, NC, TX | View Drugs | View Results |
Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers | ZEN-3694 | ZEN003694, BET bromodomain inhibitor ZEN-3694 | BET inhibitor | Clinical Trials |
|
|
| NCT05335993 | II | Platinum sensitive high grade serous ovarian cancer with CA125-associated recurrence | Phase 2, Single Arm Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Niraparib as a Combinatorial Immune Priming Strategy in Subjects With Platinum Sensitive Recurrent Ovarian Cancer | NC, OK, VA | View Drugs | |
Niraparib | Zejula, MK4827 | PARP inhibitor | Approved in Ovarian Cancer | Oregovomab | OvaRex, Monoclonal Antibody B43.13, B43.13 | Immune response against cancer expressing CA125 | Clinical Trials |
|
|
| NCT05337735 | II | Advanced solid tumors with dMMR or high MSI | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers | TX | View Drugs | View Results |
Vudalimab | XmAb717, anti-PD1/CTLA4 bispecific antibody XmAb20717, XmAb20717 | Blocks PD-1 and CTLA-4 inhibition of T cells | Clinical Trials |
|
|
| NCT05489211 | II | Advanced solid tumors | A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours (TROPION-PanTumor03) | CA, IN, MA, MI, NJ, NM, NY, OH, TN, TX, WI | View Drugs | View Results |
AZD5305 | | PARP1 inhibitor | Clinical Trials | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Datopotamab deruxtecan | Anti-TROP2/DXd antibody-drug conjugate DS-1062a, Dato-DXd | ADC: anti-TROP2 + topoisomerase I inhibitor (Dxd) | Clinical Trials |
|
|
| NCT05512208 | II | Recurrent high grade serous, endometrioid or mucinous ovarian cancer with alterations in RAS, BRAF or NF1 | A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Plus Defactinib (FAK Inhibitor) in Recurrent Gynecological Cancers (DURAFAK) | OK | View Drugs | View Results |
Avutometinib | CH5126766, Raf/MEK dual kinase inhibitor RO5126766, RO5126766, CKI27, VS-6766 | RAF and MEK inhibitor | Clinical Trials | Defactinib | VS-6063, PF-04554878, PF-04554878 | FAK inhibitor | Clinical Trials |
|
|
| NCT05523440 | II | Recurrent ovarian cancer with ARID1A mutations | Phase 2 Trial of Niraparib or Niraparib and Bevacizumab Combination in Patients With Recurrent Endometrial Cancer and/or Ovarian Cancer With ARID1A Mutation (OU-SCC-ARID1A) | OK | View Drugs | |
|
|
| NCT05503797 | II | Advanced solid cancers with a BRAF fusion | A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations | CA, FL, MO, NE, OH | View Drugs | |
Plixorafenib | 8394, BRAF inhibitor PLX8394, FORE8394 | BRAF kinase inhibitor | Clinical Trials |
|
|
| NCT05147558 | II | Recurrent carcinosarcoma | A Phase II Trial of Pembrolizumab Plus Lenvatinib for the Treatment of Patients With Advanced Uterine and Ovarian Carcinosarcomas | NJ, NY | View Drugs | View Results |
Lenvatinib | MK-7902, Lenvima, ER-203492-00, E7080 | Multi-targeted RTK inhibitor | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05634785 | II | Advanced CD30+ nonseminomatous germ cell tumors | Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Patients With CD30+ Nonseminomatous Germ Cell Tumors (NSGCT) | NC | View Drugs | |
ATLCAR.CD30 | autologous CD30CAR-CD28-CD3zeta-expressing T lymphocytes | Immune response against cancer expressing CD30 | Clinical Trials |
|
|
| NCT05661578 | II | Advanced PD-L1+ solid tumors | A Phase II, Single-Arm, Open-Label Study Evaluating the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors | WA | View Drugs | View Results |
Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Tiragolumab | MTIG7192A, RO7092284 | Blocks TIGIT binding to PVR (CD155) and PVRL2 (CD112) to enable DNAM-1 (CD226) mediated activation of NK and CD8 T cells | Clinical Trials |
|
|
| NCT05673928 | II | Advanced HER2+ solid tumors with brain metastases | A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB) | TX | View Drugs | |
Trastuzumab emtansine | trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine | ADC: anti-HER2 + microtubule destabilizer (DM1) | Approved in Other Cancers | Tucatinib | Irbinitinib, ONT-380 | HER2 kinase inhibitor | Approved in Other Cancers |
|
|
| NCT05032040 | II | Platinum resistant high grade serous or recurrent clear cell ovarian cancer (less than 2 prior chemotherapy regimens) | A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate Cancer | CA, GA, MI, NV, NY, PA | View Drugs | View Results |
Vudalimab | XmAb717, anti-PD1/CTLA4 bispecific antibody XmAb20717, XmAb20717 | Blocks PD-1 and CTLA-4 inhibition of T cells | Clinical Trials |
|
|
| NCT04332653 | Ib/IIa | Advanced solid tumors (Phase II) | An Open-label Phase 1b/2a Study of NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Advanced Solid Tumors | FL, MI, MO, NC, PA, TN, TX | View Drugs | View Results |
Efineptakin alfa | NT-I7, GX-I7, Hyleukin, recombinant human IL-7-hybrid Fc NT-I7, TJ107 | IL-7R agonist | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05700669 | Ib/II | Recurrent ovarian cancer | A Phase 1b/2 Basket Study To Assess The Safety And Efficacy Of AsiDNA™ In Combination With Olaparib In Participants With Recurrent Solid Tumors | TX | View Drugs | |
AsiDNA | DNA repair inhibiting oligonucleotide | DNA Repair decoy | Clinical Trials | Olaparib | Lynparza, AZD2281 | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03586661 | Ib | Recurrent high grade serous ovarian cancer with progression after platinum doublet treatment, or ovarian cancer with BRCA1/2 mutations that must have progressed after PARP inhibitor maintenance therapy (in expansion) | A Phase Ib Study of the Oral PARP Inhibitor Niraparib With the Intravenous PI3K Inhibitor Copanlisib for Recurrent Endometrial and Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | TX | View Drugs | View Results |
Copanlisib | BAY 80-6946, PI3K inhibitor BAY 80-6946 | pan-PI3K inhibitor | Approved in Other Cancers | Niraparib | Zejula, MK4827 | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03872947 | Ib | Recurrent ovarian cancer | A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors | AZ, CA, LA, NJ, NY, OR, TX, VA, WI | View Drugs | View Results |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Topotecan | Hycamptamine, Hycamtin, TOPO | Topoisomerase I inhibitor | Approved in Ovarian Cancer | TRK-950 | monoclonal antibody TRK-950 | Undisclosed mechanism | Clinical Trials |
|
|
| NCT03842228 | Ib | Advanced solid tumors with alterations in BARD1, BRCA1/2, BRIP1, FANCA, NBN, PALB2, PIK3CA (E542, E545 or H1047), PTEN, RAD51, RAD51B/C/D (in expansion) | A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and Durvalumab (MEDI4736) in Patients With Advanced Solid Tumors | CO, MA, TX | View Drugs | View Results |
Copanlisib | BAY 80-6946, PI3K inhibitor BAY 80-6946 | pan-PI3K inhibitor | Approved in Other Cancers | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Olaparib | Lynparza, AZD2281 | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04244552 | Ib | Advanced solid tumors (ATRC-101) or high grade serous platinum resistant or refractory ovarian cancer (ATRC-101+PLD) | A Phase 1b Dose Escalation and Expansion Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 as Monotherapy and in Combination With Other Anticancer Agents in Adults With Advanced Solid Malignancies | AZ, CA, DC, FL, MA, MN, NE, NY, NC, OH, OK, TN, TX | View Drugs | View Results |
ATRC-101 | | Anti-tumor immune response | Clinical Trials | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04130516 | I/IIa | Advanced solid tumors with prior PD-1/PD-L1 inhibitor therapy (Phase II) | A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab | CA, CT, MA, NM, NY, PA, TX | View Drugs | View Results |
LNS8801 | G protein-coupled estrogen receptor agonist LNS8801 | GPER agonist | Clinical Trials |
|
|
| NCT02484404 | I/II | Recurrent ovarian cancer (Phase II) | Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers | MD | View Drugs | View Results |
Cediranib | Recentin, Cediranib maleate, AZD2171 | VEGFR1-3 kinase inhibitor | | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Olaparib | Lynparza, AZD2281 | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03400332 | I/II | Advanced solid tumors (Phase II) | A Phase 1/2 Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers | AR, CA, GA, MD, MA, NE, NJ, OK, PA, UT, VA | View Drugs | View Results |
HuMax-IL8 | MDX 018, anti-IL-8 monoclonal antibody HuMax-IL8, BMS-986253 | IL-8 antagonist | Clinical Trials | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03157128 | I/II | Advanced solid tumors with RET alterations (Phase II) | A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001) | AZ, CA, CO, CT, DC, FL, GA, IL, LA, MD, MA, MI, MN, MO, NV, NY, NC, OH, OR, PA, TN, TX, UT, VA, WI | View Drugs | View Results |
Selpercatinib | LOXO-292, RET kinase inhibitor LOXO-292, Retevmo | RET-kinase inhibitor | Approved in Other Cancers |
|
|
| NCT03767348 | I/II | Advanced solid tumor with high MSI or dMMR who have progressed on prior PD-1/PD-L1 inhibitor therapy - intratumoral injection (Phase II) | An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors | AZ, AR, CA, FL, IA, KY, MN, NJ, NY, NC, OH, SC, TN, TX, UT, WA, WI | View Drugs | View Results |
Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | RP1 | oncolytic virus RP1, A genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus | Induces immune response and tumor cell lysis | Clinical Trials |
|
|
| NCT03907852 | I/II | Advanced mesothelin+ solid tumors (Phase II) | A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing Cancer | CA, FL, IL, MD, NY, NC, PA, TN, TX | View Drugs | View Results |
Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers | Gavocabtagene autoleucel | TC-210 T cells, TC-210 TruC-T cells, autologous anti-mesothelin T-cell receptor fusion construct T cells TC-210 | Immune response against cancer expressing mesothelin | Clinical Trials | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04143711 | I/II | Advanced solid tumors with ERBB2 AMP | A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications | CA, KS, LA, MD, NY, OH, PA, RI, TN, TX, WA, WI | View Drugs | |
DF1001 | HER2 tri-specific natural killer cell engager DF1001 | Re-directs NK cells and macrophages to attack HER2+ tumor cells | Clinical Trials | nab-Paclitaxel | Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007 | Microtubule stabilizer/mitotic inhibitor | NCCN Guidelines for Ovarian Cancer | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04317105 | I/II | Advanced solid tumors with PIK3CA mutations (E542, E545, or H1047) or PTEN mutations (Phase II) | A Phase I/II Biomarker Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in Patients With Advanced Solid Tumors | TX, VA | View Drugs | View Results |
Copanlisib | BAY 80-6946, PI3K inhibitor BAY 80-6946 | pan-PI3K inhibitor | Approved in Other Cancers | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT04084366 | I/II | Advanced Globo H+ solid tumors (Phase II) | A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-999 in Patients With Advanced Solid Tumors | CA, NY, TN, TX | View Drugs | View Results |
OBI-999 | anti-globo H/MMAE antibody-drug conjugate OBI 999 | ADC: anti-Globo H + microtubule destabilizer (MMAE) | Clinical Trials |
|
|
| NCT03093116 | I/II | Advanced solid tumors with ALK, ROS1 or NTRK1-3 alterations (Phase II) | A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) | CA, CO, DC, FL, GA, IL, MD, MA, MI, MN, MO, NJ, NY, NC, OH, PA, TN, TX, VA, WA, WI | View Drugs | View Results |
Repotrectinib | ALK/ROS1/NTRK/SRC multi-kinase inhibitor TPX-0005, TPX-0005 | ALK, ROS1, NTRK1-3, SRC and FAK kinase inhibitor | Clinical Trials |
|
|
| NCT03175224 | I/II | Advanced solid tumors with MET amplifications or MET gene fusions (Phase II) | Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | AZ, CA, DE, FL, MD, MA, MN, MO, NC, OH, PA, SC, TN, TX, UT, WV, WI | View Drugs | View Results |
Bozitinib | APL-101, CBT-101, Vebreltinib | c-Met kinase inhibitor | Clinical Trials |
|
|
| NCT04590326 | I/II | Recurrent ovarian cancer | Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3) | CA, FL, IL, MA, MI, NY, OH, WA | View Drugs | View Results |
Cemiplimab | anti-PD-1 monoclonal antibody REGN2810, REGN2810, Libtayo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | REGN5668 | | Stimulates CD28 to increase T cell activation and immune response against MUC16 (CA125) expressing tumor cells | Clinical Trials | Ubamatamab | anti-MUC16/CD3 bispecific antibody REGN4018, REGN4018 | Re-directs T cells to attack MUC16 (CA125)+ tumor cells | Clinical Trials |
|
|
| NCT04243499 | I/II | Recurrent ovarian cancer high levels of γ9δ2 T cells | A First-in-human, Two-part Clinical Study to Assess the Safety, Tolerability and Activity of IV Doses of ICT01 as Monotherapy and in Combination With a Checkpoint Inhibitor, in Patients With Advanced-stage, Relapsed/Refractory Cancer | CT | View Drugs | View Results |
ICT01 | | Activates gamma/delta T cells to stimulate immune response | Clinical Trials |
|
|
| NCT04875806 | I/II | Advanced B7-H4+ solid tumors (in ovarian expansion) | A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors | CT, IL, NJ, NY, NC, PA | View Drugs | View Results |
NC762 | | Blocks B7H4 inhibition of T cells | Clinical Trials |
|
|
| NCT05262530 | I/II | Recurrent CLDN6+ ovarian cancer | First-in-human, Open-label, Multicenter, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT142 in Patients With CLDN6-positive Advanced Solid Tumors | IN, MD, NY, NC, PA, TX, VA | View Drugs | |
BNT142 | BNT142 RiboMab (mRNA-encoded antibody) | Re-directs T cells to attack CLDN6+ tumor cells | Clinical Trials |
|
|
| NCT03190941 | I/II | Advanced solid tumors with a RAS G12V mutation | A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients | MD | View Drugs | |
Aldesleukin | | IL-2R agonist | Approved in Other Cancers | Anti-KRAS G12V mTCR PBL | | Immune response against cancer expressing RAS G12V | Clinical Trials | Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers |
|
|
| NCT04528836 | I/Ib | Advanced solid tumors with a KRAS G12C mutation or NF1 loss of function mutations (in expansion) | A Phase 1/1B First-in-Human Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Patients With Advanced Solid Tumors | AL, CA, CO, TX, UT, VA, WA | View Drugs | |
BBP-398 | IACS-15509 | SHP2 inhibitor | Clinical Trials |
|
|
| NCT02264678 | I | Platinum sensitive ovarian cancer with BRCA1/2, PALB2 or RAD51C/D mutations, or HRD+ that must have progressed on PARP inhibitor, no prior ATR inhibitor | A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ceralasertib in Combination With Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients With Advanced Solid Malignancies. | CA, MA, NY, PA | View Drugs | View Results |
AZD5305 | | PARP1 inhibitor | Clinical Trials | Ceralasertib | ATR kinase inhibitor AZD6738, AZD6738 | ATR kinase inhibitor | Clinical Trials | Olaparib | Lynparza, AZD2281 | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT01543763 | I | Advanced solid tumors (in ovarian expansion) | Phase I Study to Evaluate the Tolerability, Efficacy, and Safety of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors | CA | View Drugs | View Results |
Abexinostat | PCI-24781, HDAC inhibitor CRA-024781 | HDAC inhibitor | Clinical Trials | Pazopanib | Votrient | Multi-targeted RTK inhibitor | |
|
|
| NCT01376505 | I | Advanced solid tumors (in ovarian expansion) | Phase I Active Immunotherapy Trial With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like)Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine Emulsified in ISA 720 and Nor-MDP Adjuvant in Patients With Advanced Solid Tumors | OH | View Drugs | View Results |
MVF-HER-2(597-626)-MVF-HER-2 (266-296) peptide vaccine | B-Vaxx | Immune response against cancer expressing HER2 | Clinical Trials |
|
|
| NCT03054298 | I | Recurrent or persistent serous ovarian cancer | Phase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers | PA | View Drugs | View Results |
Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | huCART-meso cells | | Immune response against cancer expressing mesothelin | Clinical Trials |
|
|
| NCT03585764 | I | Recurrent or persistent FRalpha+ high grade serous ovarian cancer | Phase I Clinical Trial of Adoptive Transfer of Autologous Folate Receptor - Alpha Redirected T Cells for Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | PA | View Drugs | |
Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers | MOv19-BBz CAR T | | Immune response against cancer expressing folate receptor | Clinical Trials |
|
|
| NCT03968406 | I | Recurrent ovarian cancer (amenable to radiation therapy) - without ascites | Phase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic Cancers | TX | View Drugs | View Results |
Radiation Therapy | Irradiation, Radiotherapy | | | Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers |
|
|
| NCT04053673 | I | Advanced solid tumors with TIPARP amplification (in expansion) | A Phase 1, First-in-human Study of the Safety, Single- and Multiple-Dose Pharmacokinetics, and Preliminary Activity of Escalating Doses of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors | CO, CT, FL, MA, MO, PA, TN, TX | View Drugs | View Results |
RBN-2397 | | PARP7 inhibitor | Clinical Trials |
|
|
| NCT04149145 | I | Recurrent ovarian cancer that must have progressed on prior PARP inhibitor therapy (inc expansion) | Trial of M4344 and Niraparib in Patients With PARP Resistant Recurrent Ovarian Cancer | AL | View Drugs | View Results |
|
|
| NCT04182516 | I | Advanced solid tumors (inc ovarian expansion) | A Phase I Dose Escalation Study of NMS-03305293 in Adult Patients With Selected Advanced/Metastatic Solid Tumors | TX | View Drugs | |
NMS-03305293 | | PARP inhibitor | Clinical Trials |
|
|
| NCT04267939 | I | Advanced solid tumors with DNA Damage Repair pathway alterations, e.g. ARID1A, ATM, ATR, ATRX, BAP1, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCA , FANCC , FANCD2 , FANCE , FANCF, FANCL, MRE11A, MSH2, NBN, PALB2, PARP1, POLD1, POLE, RAD51, RAD51B, RAD51C, RAD51D, RAD54L or XRCC or CCNE1 AMP (inc ovarian expansion) | An Open-label Phase 1b Study to Determine the Maximum Tolerated and/or Recommended Phase 2 Dose of the ATR Inhibitor Elimusertib (BAY 1895344) in Combination With PARP Inhibitor Niraparib, in Participants With Recurrent Advanced Solid Tumors and Ovarian Cancer | MA, NY, TX | View Drugs | View Results |
Elimusertib | ATR kinase inhibitor BAY1895344, BAY1895344 | ATR kinase inhibitor | Clinical Trials | Niraparib | Zejula, MK4827 | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04315233 | I | Recurrent serous ovarian cancer | A Phase I/Ib Trial of the CDK4/6 Antagonist Ribociclib And The HDAC Inhibitor Belinostat In Patients With Metastatic Triple Negative Breast Cancer And Recurrent Ovarian Cancer With Response Prediction By Genomics (CHARGE) | UT, VA | View Drugs | View Results |
Belinostat | PXD101 | HDAC inhibitor | Approved in Other Cancers | Ribociclib | Kisqali, CDK4/6 Inhibitor LEE011, LEE011, Kisqali | CDK4/6 inhibitor | Approved in Other Cancers |
|
|
| NCT04329494 | I | Recurrent ovarian cancer (with peritoneal disease) | Safety and Efficacy of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Ovarian, Uterine, Appendiceal, Colorectal, and Gastric Cancer Patients With Peritoneal Carcinomatosis (PC) | CA, FL, NY | View Drugs | View Results |
Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | Doxorubicin | 14-Hydroxydaunomycin, Hydroxyl-Daunorubicin | Topoisomerase II inhibitor | Approved in Other Cancers | PIPAC | pressurized intraperitoneal aerosol chemotherapy | | Clinical Trials |
|
|
| NCT04257110 | I | Advanced HER2+ solid tumors (in expansion) | A First-in-human, Open Label, Multiple Dose, Dose Escalation and Cohort Expansion Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors | CA, TN, VA | View Drugs | |
BB-1701 | | ADC: anti-HER2 + microtubule destabilizer (eribulin) | Clinical Trials |
|
|
| NCT04526106 | I | Advanced solid tumors with FGFR2 alterations (in expansion) | A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors | AZ, CA, FL, GA, IL, MA, MI, MN, NY, OH, PA, TX, UT, WA | View Drugs | |
RLY-4008 | | FGFR2 inhibitor | Clinical Trials |
|
|
| NCT04608409 | I | Partially platinum sensitive, platinum resistant or refractory ovarian cancer | A Phase I Dose-Escalation Study on the Safety of Lapatinib With Dose-Dense Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer | KY | View Drugs | |
Lapatinib | GW2016, GSK572016, lapatinib ditosylate, Tykerb | EGFR and HER2 kinase inhibitor | Approved in Other Cancers | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04044859 | I | Advanced MAGE-A4+ solid tumors (in expansion) | A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 As Monotherapy Or In Combination With Either Nivolumab Or Pembrolizumab In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | FL, MA, MO, NY, NC, OK, TN, TX, WI | View Drugs | View Results |
ADP-A2M4CD8 | SPEAR T-cell ADP-A2M4CD8, autologous genetically-modified MAGE-A4 C1032 CD8alpha T cells | Immune response against cancer expressing MAGE-A4 | Clinical Trials |
|
|
| NCT04673448 | I | Recurrent ovarian cancer with BRCA1/2 mutations | Phase IB Trial of Niraparib and TSR-042 in Patients With BRCA-Mutated Breast, Pancreas or Ovary Cancer | WA | View Drugs | View Results |
Dostarlimab | TSR-042, anti-PD-1 monoclonal antibody TSR-042, ANB011 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Niraparib | Zejula, MK4827 | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04682431 | I | Advanced solid tumors (in expansion) | A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY159 as a Single Agent and In Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | CA, CO, CT, FL, IN, MA, MI, NJ, OH, OK, OR, PA, TX | View Drugs | |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | PY159 | | Activates TREM1 signaling to repolarize suppressive tumor-associated myeloid cells to induce a proinflammatory phenotype | Clinical Trials |
|
|
| NCT04703920 | I | Recurrent high grade serous ovarian cancer | A Phase 1 Dose-Escalation Trial of Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer | MI | View Drugs | View Results |
Belinostat | PXD101 | HDAC inhibitor | Approved in Other Cancers | Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers |
|
|
| NCT04707248 | I | Recurrent ovarian cancer (in expansion) | Phase I, Two-Part, Multi-Center, First-in-Human Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors | AZ, CO, FL, OK, TN | View Drugs | View Results |
DS-6000a | | ADC: anti-CDH6 + topoisomerase I inhibitor (Dxd) | Clinical Trials |
|
|
| NCT04718675 | I | Recurrent ovarian cancer with MYC overexpression or MYC amplification (inc expansion) | Phase 1, First-in-human, Open-label Dose Escalation and Cohort Expansion Study of KB-0742 in Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma | CA, IN, MA, MO, TN, TX | View Drugs | |
KB-0742 | | CDK9 inhibitor | Clinical Trials |
|
|
| NCT04890613 | I | Ovarian cancer with germline BRCA2 or germline PALB2 alterations, or high grade serous or endometrioid ovarian cancer with BRCA1 alterations or other HRD-associated mutations | Phase Ib Expansion Study of CX-5461 in Patients With Solid Tumours and BRCA2 and/or PALB2 Mutation | CA, FL, MA, OH, PA | View Drugs | View Results |
Pidnarulex | Pol I inhibitor CX5461, RNA Pol I inhibitor CX5461, CX-5461 | Pol I inhibitor | Clinical Trials |
|
|
| NCT04907968 | I | Platinum sensitive ovarian cancer (in expansion) | Upifitamab Rilsodotin (Xmt-1536) An Open-Label, Multicenter, Dose Escalation And Expansion Study Of Upifitamab Rilsodotin In Combination With Carboplatin In Participants With High Grade Serous Ovarian Cancer (Upgrade-A) | AZ, MI, NY, OH, OR, PA, SD, TN, TX, UT, VA | View Drugs | View Results |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Upifitamab rilsodotin | XMT-1536, UpRi | ADC: anti-NaPi2b + microtubule destabilizer (auristatin F-HPA) | Clinical Trials |
|
|
| NCT05057715 | I | Persistent or recurrent serous ovarian cancer | Phase 1 Trial of Human Chimeric Antigen Receptor Modified T Cells (huCART-meso) Administered in Combination With VCN-01 in Patients With Pancreatic and Serous Epithelial Ovarian Cancer | PA | View Drugs | View Results |
huCART-meso cells | | Immune response against cancer expressing mesothelin | Clinical Trials | VCN-01 | PH20 hyaluronidase-expressing adenovirus VCN-01 | Induces immune response and tumor cell lysis | Clinical Trials |
|
|
| NCT05216432 | I | Advanced solid tumors (inc ovarian expansion) | A First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer | AZ, CO, FL, MA, NY, TN, TX, VA, WI | View Drugs | View Results |
RLY-2608 | | PI3K alpha inhibitor | Clinical Trials |
|
|
| NCT05229900 | I | Advanced solid tumors (inc ovarian expansion) | A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors | CA, CT, FL, MI, OK, UT, VA | View Drugs | |
SGN-ALPV | | ADC: anti-ALPP + microtubule destabilizer (MMAE) | Clinical Trials |
|
|
| NCT05238922 | I | Advanced solid tumors (inc ovarian expansion) | A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors | CA, CO, CT, GA, NY, NC, PA, TX | View Drugs | |
INCB123667 | | CDK2 inhibitor | Clinical Trials |
|
|
| NCT05271318 | I | Recurrent ovarian cancer | A Phase I Open-Label, Dose-escalation Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Combination With Pembrolizumab in Patients With Platinum Resistant or Refractory Ovarian Cancer | MN | View Drugs | |
Igrelimogene litadenorepvec | TNFalpha/IL-2-encoding oncolytic adenovirus TILT-123, Ad5/3-E2F-d24-hTNFa-IRES-hIL2, TILT-123 | Induces immune response and tumor cell lysis | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05300048 | I | Advanced solid tumors with PIK3CA mutations (inc ovarian expansion) | A Phase 1b Study of Serabelisib in Combination With an Insulin Suppressing Diet (Study ISD) and With or Without Nab-paclitaxel in Adult Subjects With Advanced Solid Tumors With PIK3CA Mutations With or Without PTEN Loss | AL, CA, IN, MN, NY, NC, PA, SD, TX | View Drugs | View Results |
nab-Paclitaxel | Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007 | Microtubule stabilizer/mitotic inhibitor | NCCN Guidelines for Ovarian Cancer | Serabelisib | PI3K alpha inhibitor MLN1117, TAK-117, INK-1117, MLN1117 | PI3K alpha inhibitor | Clinical Trials |
|
|
| NCT03448042 | I | Advanced HER2+ solid tumors (in expansion) | A Phase Ia/Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Runimotamab Administered Intravenously as a Single Agent and in Combination With Trastuzumab in Patients With Locally Advanced or Metastatic HER2-Expressing Cancers | NY, TN | View Drugs | |
Runimotamab | BTRC 4017A, anti-HER2 x anti-CD3 bispecific monoclonal antibody BTRC 4017A | Re-directs T cells to attack HER2+ tumor cells | Clinical Trials | Trastuzumab | Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody | HER2 antagonist | Approved in Other Cancers |
|
|
| NCT05360680 | I | Advanced WT-1+ solid tumors (inc ovarian expansion) | A Phase 1, Open-Label, Dose Escalation and Expansion Study of CUE-102 Monotherapy in HLA-A*0201 Positive Patients With WT1 Positive Recurrent/Metastatic Cancers | FL, GA, MD, NY, NC, OH, TX, WA, WI | View Drugs | |
CUE-102 | WT1-targeted IL-2-based fusion protein CUE-102 | Immune response against cancer expressing WT1 | Clinical Trials |
|
|
| NCT05417594 | I | Recurrent ovarian with cancer with a BRCA1/2, PALB2 or RAD51C/D alteration (at most 1 prior PARP inhibitor therapy) | A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1) | CA, IL, MA, NY, OR, TX | View Drugs | |
AZD9574 | | PARP1 inhibitor | Clinical Trials |
|
|
| NCT05527184 | I | Recurrent high grade serous ovarian cancer (inc expansion) | A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers | CA, CO, FL, OK, TN, TX | View Drugs | |
IMGN151 | | ADC: anti-FOLR1 + microtubule destabilizer (DM21) | Clinical Trials |
|
|
| NCT03401385 | I | Advanced solid tumors (in expansion) | Phase 1, Two-part, Multicenter, Open-label, Multiple Dose, First-in-human Study of DS-1062a in Subjects With Advanced Solid Tumors (TROPION-PanTumor01) | CA, DC, GA, MD, MA, NY, TN, TX, VA | View Drugs | View Results |
Datopotamab deruxtecan | Anti-TROP2/DXd antibody-drug conjugate DS-1062a, Dato-DXd | ADC: anti-TROP2 + topoisomerase I inhibitor (Dxd) | Clinical Trials |
|
|
| NCT03745326 | I | Advanced solid tumors with a RAS G12D mutation | A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients | MD | View Drugs | |
Aldesleukin | | IL-2R agonist | Approved in Other Cancers | Anti-KRAS G12D mTCR PBL | | Immune response against cancer expressing RAS G12D | Clinical Trials | Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers |
|
|
| NCT05708924 | I | Recurrent ovarian cancer - intraperitoneal infusion | MT2021-27 Intraperitoneal FT538 With Intravenous Enoblituzumab in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | MN | View Drugs | |
Enoblituzumab | mab MGA271, MGA271 | Immune response against cancer expressing B7H3 | Clinical Trials | FT538 | iPSC-derived CD16/IL-15RF-expressing CD38-eliminated NK Cells FT538 | Anti-tumor immune response | Clinical Trials |
|
|
| NCT04847063 | I | Newly diagnosed or recurrent ovarian cancer with peritoneal disease | Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies | MD | View Drugs | |
Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | Doxorubicin | 14-Hydroxydaunomycin, Hydroxyl-Daunorubicin | Topoisomerase II inhibitor | Approved in Other Cancers | HIPEC | Hyperthermic Intraperitoneal Chemotherapy | | NCCN Guidelines for Ovarian Cancer | Oxaliplatin | OHP, Eloxatine, Dacplat, Dacotin, Eloxatin | DNA damaging agent | | Surgery | | | Clinical Trials |
|
|
| NCT05039801 | I | Advanced solid tumors with KEAP1, NF1, NFE2L2, or STK11 (LKB1) alterations, or platinum resistant or refractory high grade serous ovarian cancer with low expression of ASNS, or recurrent clear cell ovarian cancer with an ARID1A mutation or platinum resistant or refractory high grade ovarian cancer (combo w/ paclitaxel and bevacizumab) (inc expansion) | A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors | TX | View Drugs | View Results |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | IACS-6274 | glutaminase inhibitor IPN60090, IPN60090 | Glutaminase inhibitor | Clinical Trials | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|